Effect of Finerenone on Myocardial Fibrosis and Cardiac Function in HFmrEF/HFpEF Patients

A phase 4 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 104 participants.

Also called NCT07583173

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; triple masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 104 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT07583173
Planned start
(anticipated) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
China (from the registry)
Registry status
  • Not yet recruiting (from the registry)

Technical summary

Registry record NCT07583173. Randomized; triple masking; primary purpose treatment. Start 2026-05-15 (anticipated); primary completion 2027-10-31 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Effect of Finerenone on Myocardial Fibrosis and Cardiac Function in HFmrEF/HFpEF Patients
Acronym
FINE-FOCUS
Condition
Heart Failure
Intervention (Drug)
Oral finerenone
Intervention (Drug)
Placebo
Lead sponsor
China National Center for Cardiovascular Diseases (class: other government)

Record details

Record id
cardio:ct-nct07583173
Content hash
cb37fb98c4804f3a03e8de6f9eae91b8ef7517c4c494a867698d14d4226d3cf8